Veklury to Join NHI Price List to Enter Normal Distribution Channel; Peak Sales Put at 18 Billion Yen

Fifteen months after obtaining approval as the first COVID-19 drug in Japan, Gilead Sciences’ Veklury (remdesivir) is soon to join the NHI price list, which will pave the way for it to be traded under the ordinary distribution channel, according...read more